This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cyclacel Pharmaceuticals, Inc.
Drug Names(s): CYC202, R-roscovitine
Description: Seliciclib (CYC202 or R-roscovitine) is a potent inhibitor of cyclin dependent kinases including CDK2/cyclin E, CDK7/cyclin H and CDK9/cyclin T. Seliciclib induces cell apoptosis.
Cyclacel and ManRos
In June 2015, Cyclacel and ManRos Therapeutics announced the execution of a collaboration, licensing and supply agreement for the exclusive development and commercialisation of Cyclacel's oral seliciclib capsules by ManRos as a treatment for cystic fibrosis (CF). Among other terms of the agreement ManRos licensed rights to Cyclacel's proprietary clinical data to enable clinical development of seliciclib for cystic fibrosis indications.
The agreement provides for Cyclacel supply of seliciclib investigational product for initial and later stage clinical trials of seliciclib in CF and technical assistance related to Cyclacel's know-how to facilitate these trials. Cyclacel will receive an up-front payment, milestone payments and tiered royalties, if seliciclib is commercialized for the treatment of CF. Financial details were not disclosed.
Partners: ManRos Therapeutics
Additional information available to subscribers only: